Sierra Oncology, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | |
|---|---|---|---|---|---|---|
| Revenue | — | $300,000 | — | — | — | — |
| Operating income | −$94.6M | −$64.9M | −$67.0M | −$55.4M | −$42.6M | −$48.1M |
| Net income | −$94.7M | −$80.9M | −$88.3M | −$53.3M | −$42.0M | −$47.9M |
| Total assets | $109.4M | $107.5M | $151.3M | $109.5M | $102.2M | $111.0M |
| Total liabilities | $13.4M | $9.5M | $65.0M | $15.0M | $7.5M | $7.7M |
| Equity | $96.0M | $98.0M | $86.3M | $94.5M | $94.7M | $103.2M |
| EPS (diluted) | — | — | — | — | — | — |
| Shares out. | 11.6M | 10.4M | 74.5M | 52.5M | 52.2M | 30.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2021- Operating margin
- —
- Net margin
- —
- Return on equity
- −98.6%
- Return on assets
- −86.6%
- Return on capital (ROCE)
- −98.0%
- Liabilities / assets
- 12.2%
- Debt / equity
- 0.14×
- Book value / share
- $8.26
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2021- Altman Z″ (distress)
- -20.66distress
- Accruals / assets
- −14.4%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Vivo Opportunity, LlcDirector | Jul 1, 2022 | D | 161,712 | $55.00 |
| Orbimed Advisors LlcDirector | Jul 1, 2022 | D | 1.5M | $55.00 |
| Ashiya MonaDirector | Jul 1, 2022 | D | 1.5M | $55.00 |
| Aggarwal GauravDirector | Jul 1, 2022 | D | 2.7M | $55.00 |
| Sinclair AndrewDirector | Jul 1, 2022 | D | 1.3M | $55.00 |
| Klencke BarbaraOfficer — Chief Medical Officer | Jul 1, 2022 | D | 10,000 | $55.00 |
| Allen Andrew RDirector | Jul 1, 2022 | D | 1,650 | $55.00 |
| Collard Craig ADirector | Jul 1, 2022 | D | 13,500 | $55.00 |
| Dilly Stephen GeorgeOfficer — CEO and President | Jul 1, 2022 | D | 5,000 | $55.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsJul 1, 2022
- Shareholder vote · Other material eventJun 29, 2022
- Other material eventJun 22, 2022
- Other material eventJun 1, 2022
- Results of operationsMay 6, 2022
- Entered a material agreement · Other material eventApr 13, 2022
- Director / officer changeMar 23, 2022
- Results of operationsMar 10, 2022
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/AFeb 14, 2023
- SC 13G/AFeb 10, 2023
- SC 13D/AJul 11, 2022
- 15-12GJul 11, 2022
- EFFECTJul 7, 2022
- EFFECTJul 7, 2022
- SC 13G/AAMENDMENT NO. 4 TO SCHEDULE 13GJul 5, 2022
- 4Jul 1, 2022
- 4FORM 4 SUBMISSIONJul 1, 2022
- 4FORM 4 SUBMISSIONJul 1, 2022
- 4FORM 4 SUBMISSIONJul 1, 2022
- 4Jul 1, 2022
- 4FORM 4 SUBMISSIONJul 1, 2022
- 4FORM 4 SUBMISSIONJul 1, 2022
- 4FORM 4 SUBMISSIONJul 1, 2022
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.